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We sought to find a urinary biomarker for chronic kidney
disease and tested hematopoietic growth factor inducible
neurokinin-1 (HGFIN, also known as Gpnmb/Osteoactivin) as
it was found to be a kidney injury biomarker in microarray
studies. Here, we studied whether HGFIN is a marker of
kidney disease progression. Its increase in kidney disease
was confirmed by real-time PCR after 5/6 nephrectomy, in
streptozotocin-induced diabetes, and in patients with chronic
kidney disease. In the remnant kidney, HGFIN mRNA
increased over time reflecting lesion chronicity. HGFIN was
identified in the infarct portion of the remnant kidney in
infiltrating hematopoietic interstitial cells, and in distal
nephron tubules of the viable remnant kidney expressed
de novo with increasing time. In vitro, it localized to
cytoplasmic vesicles and cell membranes. Epithelial cells
lining distal tubules and sloughed luminal tubule cells of
patients expressed HGFIN protein. The urine HGFIN-to-
creatinine ratio increased over time after 5/6 nephrectomy;
increased in patients with proteinuric and polycystic kidney
disease; and remained detectable in urine after prolonged
freezer storage. The urine HGFIN-to-creatinine ratio
compared favorably with the urine neutrophil gelatinase-
associated lipocalin (NGAL)-to-creatinine ratio (both
measured by commercial enzyme-linked immunosorbent
assays (ELISAs)), and correlated strongly with proteinuria,
but weakly with estimated glomerular filtration rate and
serum creatinine. Thus, HGFIN may be a biomarker of
progressive kidney disease.
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Hematopoietic growth factor inducible neurokinin-1
(HGFIN) is a single-pass type 1 transmembrane protein
cloned in rats, humans, and mice.1–3 It is widely expressed.3–9
It has short intracellular domain (ICD) and transmembrane
domain and a long extracellular domain. Its extracellular
domain includes PKD1 (polycystic kidney disease 1), heparin
binding, RGD integrin binding, and PRRD (proline-rich
repeat domains).9,10 The ICD has a dileucine repeat and an
immunoreceptor tyrosine-based activation motif (ITAM).9
They regulate autophagosome and lysosome trafficking.7,10,11
In microarrays, renal HGFIN was increased in rats with
sevoflurane toxicity,12 and in aging human kidney13 and
human diabetic nephropathy (DN).14 HGFIN mRNA and
protein are increased after ureteral obstruction in rats.15
We tested whether HGFIN performs well as a kidney injury
biomarker.
RESULTS
HGFIN mRNA is increased after 5/6 nephrectomy
(5/6Nx) in rat remnant kidney (RK)
Affymetrix chip 230_2 (Santa Clara, CA) identified incre-
ments in HGFIN-expressed sequence tags: 56-, 33-, and
28-fold at 2 days, 2 weeks, and 4 weeks after 5/6Nx (n¼ 3,
each time point versus control). Results were corroborated by
real-time quantitative PCR: HGFIN mRNA was increased 50-
fold at 2 days (Po0.001), 48-fold at 2 weeks (Po0.001), and
42-fold at 4 weeks (Po0.001; Figure 1a). These data were
obtained with RK inclusive of infarct. Additional surgeries
(n¼ 7 at each time point) ascertained the contribution of
viable RK by infarct excision. Real-time PCR showed that
although the magnitude of HGFIN mRNA was less in viable
RK (Figure 1b), the change remained significant. Increasing
expression over time was appreciated after infarct excision.
Thus, both viable RK and the infarct express large amounts of
HGFIN mRNA after injury. The relative contribution from
the RK increases over time.
HGFIN is normally expressed in rat medulla, but not in
cortical tubules. After 5/6Nx, cortical distal nephron tubules
express HGFIN. HGFIN is physiologically expressed in
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medullary collecting tubules (Figure 2a) but is imperceptible
in control cortical tubules (Figure 2b). The HGFIN mRNA
increment at 2 days after 5/6Nx is predominantly attributable
to infiltrating cells in the infarct (Figure 2c). In viable RK,
HGFIN protein is expressed in cortical tubules 2 days after
5/6Nx (Figure 2d), increases over 2–4 weeks (Figure 2e and f),
and appears in luminal tubule cells and fragments
(Figure 2f). HGFIN co-staining with peanut agglutinin, but
not PHA-E (Phaseolus vulgaris erythroagglutinin), demon-
strates distal but not proximal tubular expression with injury
(Figure 2g and h). Medullary HGFIN staining intensity
measured by Image-Pro Plus software (Bethesda, MD) was
not different in control and 5/6Nx rats (n¼ 3/group, each
time period). Semiquantitation of medullary HGFIN dis-
tribution and intensity in 5/6Nx vs controls confirmed that
neoexpression in distal nephron cortical tubules, and not
differential medullary expression, is the source of the
increment (data not shown). To localize at the cellular level,
GFP-HGFIN was overexpressed in mouse distal convoluted
tubule (MDCT) cells. Confocal microscopy showed coarse
granular intracytoplasmic HGFIN staining (green, Figure 3a),
linear cell membrane staining for a1 Na,K-ATPase (red,
Figure 3b), and nuclear staining using TO-PRO-3 (blue,
Figure 3c). On merging, the orange cell membrane
color change demonstrates colocalization of HGFIN and a1
Na,K-ATPase. Thus, after 5/6Nx, HGFIN is heavily expressed
in infiltrating hematopoietic cells in the infarct and
incrementally over time in distal nephron cortical tubules
and tubule cells that were shed into the lumen.
Urine HGFIN/creatinine (uHGFIN/cr) increases over time
after 5/6Nx
Urine was collected from rats preoperatively, and at 2 days,
2 weeks, and 4 weeks after 5/6Nx (n¼ 3, each time point).
Melanoma lysate was used as positive HGFIN control (not
shown). uHGFIN/cr was detected by immunoblotting
(Figure 4) and increased with lesion chronicity. Thus,
uHGFIN/cr distinguished healthy from injured kidney
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Figure 1 |Hematopoietic growth factor inducible neurokinin-1
(HGFIN)/18S mRNA is increased in kidney lysate after 5/6
nephrectomy (5/6Nx). (a) By real-time PCR, HGFIN/18S was
increasedB45–50-fold in the remnant kidney (RK), inclusive of the
infarct zone (n¼ 6) compared with controls (n¼ 6). (b) By real-time
PCR, HGFIN/18S increased over time in the RK when tested with
the infarct zone excised (n¼ 7) compared with controls (n¼ 7).
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Figure 2 |Hematopoietic growth factor inducible neurokinin-1 (HGFIN) expression and localization in normal kidney and after
5/6 nephrectomy (5/6Nx). (a) In control kidney, immunoperoxidase staining demonstrates HGFIN normally expressed in collecting tubule
cells in deep medulla (brown staining; hematoxylin counterstain, original magnification  400). (b) HGFIN is below detection (or
occasionally barely detectable) in tubules in control cortex (hematoxylin counterstain, original magnification  200). (c) HGFIN is heavily
expressed in infiltrating cells in the infarcted tubulointerstitial region 2 days after 5/6Nx (brown staining; hematoxylin counterstain, original
magnification  200). (d) In the surviving RK, HGFIN protein is expressed faintly in cortical tubule cells 2 days after 5/6Nx (faint brown
staining, arrow; hematoxylin counterstain, original magnification  200). (e, f) HGFIN expression increases over 2–4 weeks, and is expressed
in tubule cells that are shed into the lumen (hematoxylin counterstain, original magnification  200, arrow showing sloughed tubule cells
in f). (g, h) Double immunofluorescence staining demonstrated HGFIN colocalizing with distal tubule marker peanut agglutinin (PNA; g), but
not with proximal tubule marker Phaseolus vulgaris erythroagglutinin (PHA-E; h). Control sections incubated with normal serum without
primary antibody or with polyclonal IgG instead of primary antibody followed by secondary antibody showed no staining (data not shown).
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categorically and distinguished early from chronic injury
by range values that increased with chronicity of injury.
HGFIN mRNA is increased in rat kidney cortex in
streptozotocin (SZ)-induced diabetes (DM; SZ-DM)
HGFIN mRNA was measured by real-time PCR in rat renal
cortex 4 months after SZ-DM induction to examine a lesion
without infarction. Previous work showed chronic tubuloin-
terstitial changes by 4 weeks,16 and albuminuria and histo-
logical changes by 3 to 4 months.17 Figure 5a shows an
11-fold increase in renal cortical HGFIN mRNA versus
controls, supporting generalizability of HGFIN as a kidney
injury biomarker.
Renal cortical HGFIN mRNA is increased in microalbu-
minuric and overtly proteinuric patients with type 1 diabetes
mellitus (DM) compared with normoalbuminuric (NA) DM
patients and live renal donors. We showed that glomerular
collagen IV and connective tissue growth factor mRNA are
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Figure 3 |Hematopoietic growth factor inducible neurokinin-1
(HGFIN) localizes to cytoplasmic vesicles and the cell
membrane in mouse distal convoluted tubule (MDCT) cells.
Immortalized MDCT cells were transfected with pEGFP-mHGFIN,
fixed, washed, and labeled with a1 Na,K-ATPase antibody
followed by Alexa Fluor 563 goat anti-mouse secondary antibody.
Nuclei were labeled with TO-PRO-3 iodide. Slides were examined
using a confocal laser scanning microscope. (a) Coarse granular
intracytoplasmic staining for HGFIN (green). (b) Linear cell
membrane staining for a1 Na,K-ATPase (red). (c) Nuclear staining
using To-PRO-3 (blue). (d) Merge shows orange cell membrane
color change demonstrating colocalization of HGFIN and
a1 Na,K-ATPase (original magnification  1000).
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Figure 4 |A sequential increment in urine hematopoietic
growth factor inducible neurokinin-1/creatinine (HGFIN/cr)
is demonstrable over time after 5/6 nephrectomy (5/6Nx).
Urine collected from Sprague Dawley rats housed in metabolic
cages was preserved with protease inhibitors and ice during the
collection period. Urine was collected at baseline before surgery
(pre), after which rats underwent 5/6Nx (n¼ 3). Urine was
sequentially collected from the same rats 2 days, 2 weeks, and 4
weeks after 5/6Nx. Urine HGFIN was not detected by western
immunoblotting in urine from rats during the control period
presurgery (pre). Urine HGFIN/cr was demonstrable at 2 days and
increased over the 4-week observation period.
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Figure 5 |Renal hematopoietic growth factor inducible
neurokinin-1 (HGFIN) mRNA is increased in diabetic
nephropathy (DN). (a) Sprague Dawley rats with streptozotocin
(SZ)-induced diabetes (DM; SZ-DM) for 4 months. There was an
11-fold increase in HGFIN/18S mRNA in rats with SZ-induced DN
(n¼ 5) compared with diluent-injected controls (n¼ 5). (b) In
microalbuminuric (n¼ 5) and overtly proteinuric patients (n¼ 5)
with type 1 diabetes mellitus (DM), there was a 4.5-fold increase in
renal cortical HGFIN/18S mRNA compared with normoalbuminuric
DM patients (NA, n¼ 3) and live renal donors (LRD, n¼ 6).
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increased in microalbuminuric and overtly proteinuric
patients with type 1 DM compared with NA DM patients
and live renal donors.18,19 HGFIN mRNA, measured by
semiquantitative PCR using renal cortical cDNA from those
subjects, showed a 4.5-fold increase in HGFIN/18S mRNA in
microalbuminuric (n¼ 5) and overtly proteinuric patients
(n¼ 5) compared with NA (n¼ 3) and live renal donors
(n¼ 6) (Figure 5b). These data are consistent with the
previous results in glomeruli, and establish relevance for
HGFIN measurements in patients with chronic kidney
disease (CKD).
HGFIN, autophagy, and lysosomal trafficking in injured
tubules after 5/6Nx
Dileucine repeat and ITAM motifs are constituents of HGFIN
ICD, implicated in autophagy and lysosomal function, and
modulate key cellular defenses. Serial section photomicro-
graphs of renal cortex after 5/6Nx show coexpression of
HGFIN and activated LC3 II, a major autophagy protein
(Figure 6a–d). Staining for HGFIN and phospho-Syk, a
downstream target of ITAM-phospho-Src signaling20
that regulates lysosomal function, was absent in controls
(Figure 6e and f), but colocalized in areas of tubular injury
(Figure 6g and h). These data suggest that the HGFIN ITAM
and dileucine repeats may interact functionally.
Human uHGFIN is detectable by immunoblotting in
patients with progressive proteinuric and polycystic kidney
disease but not in controls, and is recoverable from speci-
mens with and without protease inhibitors in centrifuged
urine and exosomes, and from frozen urine. uHGFIN was
measured in samples from healthy volunteers (n¼ 3) and
patients with CKD (n¼ 11; Table 1) after light centrifugation,
medium centrifugation, or ultracentrifugation for detection
in exosomes, with and without protease inhibitors (n¼ 3,
each condition). Bands were seen atB50, 65, 80, and 115 kD
(Figure 7a). The 50 kD band was the most abundant; the
65 kD band was the most consistent. We utilized the 65 kD
band for densitometry as seen by others,4,9,21,22 and corrected
for urine creatinine (uHGFIN/cr). Representative uHGFIN
bands in three proteinuric DN subjects detected under each
condition measured by immunoblotting on 5 ml samples
showed no difference in recoverable HGFIN in samples
collected and stored with or without protease inhibitors
(Figure 7b–d). HGFIN was also recoverable from samples
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Figure 6 | Immunohistochemical evidence in serial sections for hematopoietic growth factor inducible neurokinin-1 (HGFIN) as a
marker of autophagy in injured tubules after 5/6 nephrectomy (5/6Nx). (a, b) There is no immunohistochemical staining for HGFIN
(a) or LC3 II (b) in normal kidney cortex. (c, d) HGFIN (c) and LC3 II (d) colocalize in cortical distal nephron tubules after 5/6Nx. (e, f) HGFIN
(e) and phospho-Syk (f) were absent in controls. (g, h) HGFIN (g) also colocalizes with phospho-Syk (h) in cortical distal nephron tubules
after 5/6Nx (original magnification  400).
Table 1 | Clinical characteristics of the patients with proteinuric and polycystic kidney disease with uHGFIN/cr analyzed by
western immunoblotting
Etiology of CKD Age (years) Gender
Serum albumin
(g/dl)
Serum creatinine
(mg/dl) UPCR
eGFR
(ml/min per 1.73m2)
DN, n=3 57.3±16.7 M, M, F 3.1±0.5 4.0±1.0 4.4±1.4 15.8±5.8
FSGS, n=3 39.3±19.1 M, F, F 3.3±0.4 3.6±1.0 4.6±3.5 15.6±3.2
IgMN, n=1 38 M 1.7 0.9 2.9 101.5
CGN, n=1 42 F 3.6 3.2 1.32 17.0
PCKD, n=3 43.3±2.1 M, M, F 3.9±0.3 4.7±2.2 0.4±0.2 15.6±8.7
Abbreviations: CGN, chronic immunecomplex-mediated glomerulonephritis; DN, diabetic nephropathy; eGFR; estimated glomerular filtration rate; FSGS, focal and segmental
glomerulosclerosis; IgMN, IgM nephropathy; PCKD, polycystic kidney disease; uHGFIN/cr; urine hematopoietic growth factor inducible neurokinin-1/creatinine; UPCR; urine
protein–creatinine ratio.
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centrifuged lightly, more stringently, and in exosomes, but
was not recoverable from healthy controls.
uHGFIN/cr was measured by immunoblotting in patients
with polycystic kidney disease (PCKD, n¼ 3), focal and
segmental glomerulosclerosis (n¼ 3), IgM nephropathy
(n¼ 1), and immune complex glomerulonephritis (n¼ 1).
uHGFIN appeared consistently in immunoblots from
patients with nephrotic and nonnephrotic renal disease, but
not in healthy controls (Figure 8a and b). In samples frozen
for B9 years, immunoblotting showed robust bands in
overtly proteinuric DN but not in NA controls (Figure 8c).
uHGFIN/cr measured by enzyme-linked immunosorbent
assay (ELISA) distinguishes patients with renal disease
from healthy controls and compares favorably with
urinary neutrophil gelatinase-associated lipocalin/creatinine
(uNGAL/cr). Using a commercial HGFIN ELISA kit, a
standard curve was generated with recombinant HGFIN
(0.125, 0.25, 0.5, 1, 2, 4, and 8 ng/ml, r2¼ 0.997). Using urine
from a healthy control as diluent added to recombinant
HGFIN at identical concentrations resulted in a standard
curve with r2¼ 0.984, demonstrating HGFIN recoverability
from urine samples.
uHGFIN/cr was measured by ELISA in proteinuric
patients with progressive renal disease (n¼ 21), PCKD
(n¼ 5), healthy controls (n¼ 20; clinical characteristics,
Table 2), and in two patients with nonprogressive renal
disease. Samples were measured in triplicate (coefficient of
variation 12.7%). uHGFIN/cr values were not normally
distributed. Median uHGFIN/cr values in patients with
PCKD (258.7 pg/mg) trended lower than progressive protei-
nuric kidney disease (858.3 pg/mg) but were not significantly
different (P¼ 0.16). Both were higher than healthy controls
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Figure 7 |Hematopoietic growth factor inducible neurokinin-1 (HGFIN) is measurable by immunoblotting on 0.005ml urine
samples from subjects with diabetic nephropathy (DN), collected with and without protease inhibitors (PI) after centrifuging lightly
(LC), after medium centrifugation (MC), and after isolation of exosomes. (a) Urine HGFIN bands were noted atB50, 65, 80, and 115 kD.
The 50 kD band was the most abundant, but was inconsistently present. (b–d) HGFIN was recoverable from samples that were centrifuged
lightly (b, LC) or somewhat more stringently (c, MC). It was also recoverable in exosomes (d).
a LC urine HGFIN from PCKD patients w/o PI
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Figure 8 |Urine hematopoietic growth factor inducible
neurokinin-1/creatinine (uHGFIN/cr) is detectable by
immunoblotting in patients with kidney disease but not in
healthy controls. (a) In lightly centrifuged urine, 65 kDa uHGFIN
is detectable in patients with polycystic kidney disease (PCKD),
but not in controls (0.005ml urine). (b) With urine collected
identically, in patients with nephrotic forms of glomerulonephritis
but not in controls, 65 kDa uHGFIN is also clearly detectable
(representative samples). (c) Urine was collected and stored at
80 1C for B9 years. HGFIN was detectable in the urine of
subjects with overt diabetic nephropathy (DN) but not in controls.
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(median, 0 pg/mg, Po106 and Po0.01, respectively;
Figure 9a). These urines were also analyzed using a
commercially available NGAL ELISA kit. The uHGFIN/cr
and uNGAL/cr receiver operating characteristic curves
compared favorably (Figure 9b). uHGFIN/cr correlated
strongly with uNGAL/cr and proteinuria, and weakly with
estimated glomerular filtration rate and serum creatinine
(Figure 9c). uHGFIN/cr values in two patients with
nonprogressive renal disease were instructive. One had
minimal change disease with 1.2 g proteinuria despite
prednisone. The second had Wegener’s granulomatosis in
remission 410 years, but with 0.8 g proteinuria per 24 h and
stable serum creatinine at 2.0 mg/dl. In both, uHGFIN/cr was
zero. These data are consistent with the hypothesis that the
Table 2 | Clinical characteristics of the patients with proteinuric and nonproteinuric kidney disease with uHGFIN/cr
and uNGAL/cr analyzed by ELISA
Etiology of CKD
Mean age
(years) Gender
Serum
albumin
(g/dl)
BUN
(mg/dl)
Serum
creatinine
(mg/dl) UPCR
eGFR (ml/min
per 1.73m2)
Median urine
UGFIN/cr
(pg/mg)
Proteinuric patients (n=21) 46.1±14.2 F=7, M=14 3.1±0.8 49.3±26.3 3.1±1.7 4.6±2.8 35.4±34.1 853.7
DN (n=13) 52.5±10.3 F=2, M=11 3.4±0.5 60.8±19.9 3.7±1.5 4.0±1.9 20.4±6.9 858.3
GN (n=8) 35.8±14.7 F=5, M=3 2.6±1.1 30.5±25.4 2.2±1.7 5.7±3.8 59.9±46.1 971.6
LN (n=2) 20.5±2.1 F, M 2.5±0.0 46.0±46.7 2.9±3.1 4.2±1.4 59.9±62.9 20,768.0
MN (n=3) 41.0±14.4 F =2, M 2.5±1.2 31.6±18.0 2.7±1.4 7.0±1.6 34.8±31.2 757.7
IgMN (n=2) 35.5±17.7 F=2 2.6±2.1 7.5±4.9 0.7±0.2 7.4±7.8 113.4±20.8 1051.5
FSGS (n=1) 51.0 M 3.3 42.0 2.5 1.6 28.6 440.1
Nonproteinuric patients (n=5)
PCKD (n=5) 42.2±12.8 F=3, M=2 3.6±0.3 39.0±22.7 3.6±2.4 0.4±0.2 28.7±24.8 251.7
Abbreviations: BUN, blood urea nitrogen; CKD, chronic kidney disease; DN, diabetic nephropathy; eGFR; estimated glomerular filtration rate; ELISA, enzyme-linked
immunosorbent assay; FSGS, focal and segmental glomerulosclerosis; GN, glomerulonephritis; IgMN, IgM nephropathy; LN, lupus nephritis; MN, membranous nephropathy;
PCKD, polycystic kidney disease; uHGFIN/cr; urine hematopoietic growth factor inducible neurokinin-1/creatinine; uNGAL/cr, urinary neutrophil gelatinase-associated
lipocalin/creatinine; UPCR; urine protein–creatinine ratio.
0
25 50 75 100 2 4 6
–1000
0
1000
2000
3000R  =  –0.47, P  = 0.023
R = 0.83, P < 0.001 R = 0.75, P < 0.001
R = 0.49, P = 0.017
Estimated GFR (ml/min per 1.72 m2) Serum creatinine (mg/dl)
1000
2000
3000
a
b
c
Proteinuric PCKD Control
ROC curve
0.0
0.0 0.2 0.4 0.6 0.8 1.0 0
0
10,000
20,000
30,000
40,000
4 8 12 0
0
1000
2000
3000
4000
250 500 750
0.2
0.4
0.6
0.8
1.0
100
–100
300
500
700
900
2000
4000
6000
8000
10,000
30,000
40,000
50,000
Ur
in
e 
H
G
FI
N/
cr
ea
tin
in
e 
(pg
/m
g)
Ur
in
e 
H
G
FI
N 
(pg
/m
g C
r)
Ur
in
e 
H
G
FI
N 
(pg
/m
g C
r)
Ur
in
e 
H
G
FI
N 
(pg
/m
g C
r)
Urine protein–creatinine ratio (g/mg) Urine NGAL (ng/mg Cr)
Ur
in
e 
H
G
FI
N 
(pg
/m
g C
r)
Se
ns
itiv
ity
1-Specificity
Urine HGFIN (pg/mg Cr)
Urine NGAL (ng/mg Cr)
Reference line
Figure 9 |uHGFIN/cr by ELISA, and its relationship to eGFR, serum creatinine, protenuria, and uNGAL/cr. (a) Urine hematopoietic
growth factor inducible neurokinin-1/creatinine (HGFIN/cre) measured by enzyme-linked immunosorbent assay (ELISA) is higher in patients
with progressive proteinuric renal disease (n¼ 21) and in polycystic kidney disease (PCKD; n¼ 5) than in healthy controls (n¼ 20). Each
value represents the average of triplicate testing. In 3 of the 20 control subjects, there was a nonzero measured value obtained for urine
HGFIN/cre, which overlapped with values on the lower end of the spectrum observed in patients with kidney disease. The median values of
patients with progressive proteinuric disease (858.3 pg/mg) and patients with PCKD (258.7 pg/mg) were not significantly different (P¼ 0.16);
both were significantly higher than in healthy controls (0 pg/mg; Po106 and Po0.01, respectively). (b) Receiver operating characteristic
(ROC) curves for uHGFIN/cr and urinary neutrophil gelatinase-associated lipocalin/creatinine (uNGAL/cr) demonstrating comparability of the
two measures for detecting chronic kidney disease (CKD). (c) Urine HGFIN/cr values correlated strongly with urine NGAL/cre and with
proteinuria, and weakly with estimated glomerular filtration rate (eGFR) and serum creatinine.
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uHGFIN/cr measurement reflects tubular injury, and that
albuminuria/proteinuria and uHGFIN excretion are some-
what independent processes.
Case vignette
A 20-year- old woman was hospitalized  1 week with acute
lupus nephritis with 3.3 g/day proteinuria and serum
creatinine ranging from 0.9 to 1.2 mg/dl. Diuretics, losartan,
and immunosuppression were initiated. Biopsy showed
proliferative glomerulonephritis with areas of tubular
atrophy (Figure 10a). Immunoblotting detected uHGFIN/cr
in lightly centrifuged urine and exosomes (Figure 10b and c).
HGFIN immunostaining showed cortical tubular expression,
including in sloughed tubule cells (Figure 10d and e) and
atrophied tubules (Figure 10e). uHGFIN/cr was a more
sensitive reporter of tubulointerstitial injury than serum
creatinine, demonstrating potential clinical use.
DISCUSSION
These experiments show that HGFIN is a novel biomarker of
renal injury. Renal HGFIN mRNA was increased after 5/6Nx
and SZ-DM. HGFIN protein was demonstrable in hemato-
poietic interstitial cells in the infarct after 5/6Nx, de novo over
time in distal nephron cortical tubule cells in the viable
remnant renal parenchyma, and in sloughed tubule cells.
uHGFIN/cr increased over time after 5/6Nx in rats. In
MDCT cells overexpressing HGFIN, it localized to intracy-
toplasmic vesicles and cell membranes. In vivo, HGFIN
colocalized with downstream phospho-Syk, and with a key
mediator of autophagy, LC3 II, during injury, implicating
ITAM and dileucine repeat motifs in the HGFIN ICD as
potential regulators of lysosomal trafficking and autophagy
in injured tubules. Increments in renal cortical HGFIN
mRNA were also measured in patients with overt and
microalbuminuric type 1 DM, demonstrating the capacity of
the marker to identify early renal injury. By immunoblotting,
uHGFIN categorically distinguished patients with progressive
renal diseases from healthy controls. It was detectable in
samples after prolonged freezing. Using ELISA, uHGFIN/cr
distinguished controls from patients with high sensitivity and
specificity. uHGFIN/cr correlated strongly with uNGAL/cr
and proteinuria, and weakly with estimated glomerular
filtration rate and serum creatinine. These studies affirm
that HGFIN performs well as a CKD biomarker, has a
potential role in tubular cells’ response to injury, and may be
useful clinically to quantify ongoing tubular injury.
Our work does not demonstrate how HGFIN enters urine.
HGFIN/Gpnmb undergoes ectodomain shedding regulated
by calmodulin inhibitors and phorbol myristate acetate,23
matrix metalloproteases,22,24 and ADAM10 (ADAM metallo-
peptidase domain 10).25 Among species, alternate splicing
and sequence variability yields at least 13 isoforms,
contributing to molecular weight (MW) variability.4,9,21–25
We collected urine in protease inhibitors, which may also
affect the observed MW. The reported MW of HGFIN is
B65 kD; the mature glycosylated and sialylated protein
isB115 kD. Given the uHGFIN MWs in our experiments, it
is likely that most of the uHGFIN was derived from
ectodomain shedding. A minor band at 115 kD suggests that
a small amount of mature protein may also have been
released from degenerating cells. The concentration of
HGFIN in circulating blood is unknown. It is possible that
some uHGFIN comes from filtration. However, given that
patients with PCKD had urinary values that overlapped with
proteinuric patients, it is unlikely that a 50–68 kD MW
fragment in PCKD urine resulted from filtration. Further-
more, in a patient with minimal change with proteinuria, no
uHGFIN was observed. Taken together, indirect evidence
supports ectodomain shedding as the primary means by
which HGFIN enters the urine, but this will require direct
experimentation for confirmation.
A bioinformatics analysis predicted HGFIN function based
on structure.10 HGFIN’s ICD dileucine repeat and ITAM
motifs may synergize in regulating autophagy and lysosomal
function. Dileucine repeats regulate trafficking and fusion of
autophagosomes to lysosomes during autophagy.7,11 In
immune cells, activation of T- and B-cell receptors stimulate
ITAM phosphorylation by Src family tyrosine kinases,
followed by Syk recruitment and phosphorylation, the key
events in lysosome function regulation.26 Syk protein tyrosine
kinase is essential for regulating FcRg-mediated transport to
a d
eb
c
LC urine HGFIN from SLE nephritis
With PI
65 kDa
Control Patient
Urine exosomal HGFIN from
SLE nephritis
Without PI
65 kDa
Control Patient
Figure 10 |Hematopoietic growth factor inducible neurokinin-
1 (HGFIN) is demonstrable by immunohistochemistry in renal
tissue from a patient with lupus nephritis in which cortical
tubular atrophy is present before a rise in serum creatinine is
discernible. (a) Renal biopsy showed proliferative
glomerulonephritis with areas of established tubular atrophy in a
patient with lupus nephritis (Jones stain, original magnification
 100). (b, c) Immunoblotting demonstrating 65 kDa urine HGFIN
in lightly centrifuged (LC) urine and in exosomes from this patient,
but none in control. (d) HGFIN immunostaining (brown;
hematoxylin counterstain, original magnification  200) shows
tubule cell expression, including expression in sloughed tubular
cell (arrows). Inset shows sloughed tubular cell expressing HGFIN
at higher magnification (arrowhead) (e) Atrophied tubules with
thick basement membrane (arrow) and sloughed tubular cells
with HGFIN immunostaining (brown, arrowhead, original
magnification  400).
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lysosomes26,27 and for macrophage phagosome formation.28
ITAM domains are essential for integrin signaling in
hematopoietic cells.29 ITAMs have also been identified in
respiratory epithelial cells.30,31 In nonimmune cells, integrin
binding activates ITAM-cSrc-Syk signaling.30–32 In renal tubule
cells, all elements of the activation pathway are present,33,34
defining a potential pathway for regulation of lysosomal
activation and autophagy.
There are many published studies of urine biomarkers for
acute kidney injury, but fewer for CKD. Urine kidney injury
molecule-1 levels correlated with proteinuria and its change
in response to treatment better than N-acetyl glucosamini-
dase in nondiabetic proteinuric kidney disease.35 Urine
kidney injury molecule-1 also improved outcome prediction
for renal transplants better than donor age, but less so for
creatinine clearance or proteinuria.36 Serum and uNGAL
measurements were superior to estimated glomerular filtra-
tion rate in predicting clinical outcomes in CKD.37 Favorable
results were published for urinary liver-type fatty acid-
binding protein to predict a decline in creatinine clearance in
CKD.38 Although individually promising, panels of validated
biomarkers may be superior to best predict CKD outcomes.
Thus, HGFIN may be a promising CKD biomarker, alone or
in combination with others. A unique distinguishing feature
of uHGFIN is its expression in association with autophagy
markers. Indeed, this work synergizes with a recent paper by
Li et al.39 which showed that Gpnmb is necessary for
recruitment of the autophagy protein LC3 to phagosomes.
Gpnmb and LC3 colocalized in phagosomes, and Gpnmb was
required for lysosomal fusion with phagosomes, under-
scoring its role in autophagy. In vitro and in vivo, Gpnmb
mutations induced defects in renal repair.
Tubulointerstitial changes correlate well with renal func-
tional outcomes.40–42 Most data implicate proximal tubule
injury in CKD progression.43,44 However, there are argu-
ments implicating the distal nephron. Impairment of renal
concentrating capacity, denoting distal nephron injury, is a
hallmark of CKD. After acute or chronic experimental renal
injury, BMP-7 (bone morphogenetic protein 7) secretion
from the distal nephron mitigates proximal tubule injury.45
Evidence for renin activation in the distal nephron by
succinate implicate that this region in renin–angiotensin
system induced injury.46 After unilateral ureteral obstruction
in neonatal mice, tubulointerstitial fibrosis correlated with
the degree of distal tubule dilation, and apoptosis was more
prominent in the dilated distal nephron, whereas necrosis
occurred proximally.47 Indeed, although upregulated in
proximal tubules after ischemia–reperfusion injury,48 uNGAL
is now also thought to be of distal origin.49 Taken together,
these data support the proposition that distal tubule events
are markers of kidney injury.
Our observations are subject to limitations. uHGFIN is
recoverable from samples frozen for up to 9 years, but analyte
loss during storage may have occurred. Although the role of
the HGFIN dileucine repeat motif in lysosomal trafficking
and autophagy was demonstrated,7,39 evidence for the
relationship between HGFIN and LC3 II is associational.
Similarly, although ITAM motif activation in lymphocytes is
essential for lysosomal trafficking through downstream
activation of Src protein kinases and Syk phosphorylation,
its role in tubule cells requires further elucidation. Autophagy
is a key cellular adaptation to enhance cell survival in
response to injury. In the sloughed tubule cells, this
adaptation appears to fail. These observations suggest
the importance of future studies to determine whether the
HGFIN-ITAM-cSrc-Syk signaling pathway in tubule cells
represents a modifiable target to enhance cell survival.
Finally, although we have shown that uHGFIN/cr ELISA
measurements distinguish subjects with kidney diseases from
healthy controls comparing favorably with uNGAL/cr,
follow-up in larger cohorts are needed.
These studies show that uHGFIN/cr is a sensitive and
specific biomarker of distal nephron tubule injury. Additional
studies are needed to further elucidate its biologic role in
tubule cell survival during injury and to determine whether
uHGFIN/cr measurements predict clinically significant renal
outcomes.
MATERIALS AND METHODS
Animals
5/6Nx was performed in Sprague Dawley rats.50 Nx kidney was saved
for control (C). RKs were harvested after 2 days, 2 weeks, or
4 weeks (n¼ 3/time point). One section was used for immunohis-
tochemistry; the second was separated into cortex and medulla, lysed
in RIPA buffer with protease inhibitors, and placed in RNA-STAT 60
(AMS Bio, Abingdon, UK) for RNA extraction. For DM experiments,
Sprague Dawley rats received either streptozotocin 65 mg/kg intraper-
itoneally (n¼ 5) or diluent (n¼ 5), and renal cortex was harvested
after 4 months, stored in RNA-STAT 60 for RNA extraction,18 and
real-time reverse transcriptase-PCR performed.
Diabetic patients
Patients with type 1 DM (overt nephropathy (n¼ 5), micro-
albuminuria (n¼ 5), normoalbuminuria (n¼ 3), and live renal
donors (n¼ 6)) had renal biopsies, total RNA was extracted from
cortex, cDNA was synthesized, stored at 80 1C,18,19 and used for
the first time herein.
Microarray
Microarray was performed with Affymetrix chip 230_2 and analyzed
using the Gene Set Enrichment Analysis tool of the Broad Institute
(Massachusetts Institute of Technology, Boston, MA).
Real-time and semiquantitative reverse transcriptase-PCR
The HGFIN microarray result from C (n¼ 3) and 5/6Nx rats (n¼ 9)
was validated using real-time and semiquantitative reverse
transcriptase-PCR. Total RNA was extracted with RNA-STAT 60.
First-strand cDNA was synthesized from 1 mg of total RNA using a
high-capacity RNA-to-cDNA kit in a 20 ml reaction mixture
(Applied Biosystems, Foster City, CA). Primers were as follows:
Rat HGFIN F: 50-AGCACAACCAATTACGTGGC-30, R: 50-CTTCCC
AGGAGTCCTTCCA-30; Human HGFIN F: 50-TCCGACGAAACCT
TCCTCAA-30, R: 50-TCCCCGAAGCTCCACTTCTA-30; 18 s F: 50-G
GACAGGATTGACAGATTGATAGC-30, R: 50-TGGTTATCGGAAT
TAACCAGACAA-30. Real-time PCR was carried out in a 25 ml
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amplification mixture containing 0.5 ml of template cDNA, 12.5ml of
2 SYBR Green I Master Mix (Eurogentec, San Diego, CA), and
200 nmol/l sense and antisense primers. Polymerase activation step
was at 95 1C  10 min followed by 40 cycles of 95 1C  15 s and
60 1C  1 min, and run on an ABI PRISM 7000 Sequence Detector
(Applied Biosystems). A nontemplate control was included for all
primer pairs. As an internal standard, 18 s was used. Gene expression
levels from controls were set at 1 versus expression levels in
experimental groups. Real-time and semiquantitative PCR for
HGFIN on renal cortex was also performed in Sprague Dawley
control and SZ-DM rats 4 months after SZ-DM induction.
Semiquantitative PCR was performed on renal cortex from live
renal donors, and patients with type 1 diabetes with normoalbu-
minuria, microalbuminuria, and overt DN.
Immunohistochemistry
Sections (5mm) were deparaffinized and rehydrated in graded
ethanol. Endogenous peroxidase was blocked, sections microwaved
with 10 mmol/l citrate buffer (pH 6.0)  5 min, and incubated with
primary HGFIN antibody (5 mg/ml; R&D Systems, Minneapolis,
MN) at 4 1C overnight. After washing, secondary horseradish
peroxidase-conjugated donkey anti-goat antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) was added  30 min at room
temperature. Diaminobenzidine chromogen was used to develop
brown staining. Slides were counterstained with hematoxylin,
dehydrated, and mounted. As negative controls, some sections were
incubated with normal serum without primary antibody; others
were preincubated with polyclonal IgG instead of primary antibody.
Medullary HGFIN intensity was measured by software Image-Pro
Plus 6.0 under  40 magnification (12 pictures/animal) from
control (n¼ 3) and 5/6Nx rats (n¼ 3, each time period).
Double immunofluorescence staining
Renal localization. Peanut agglutinin 1 mg/ml identified dista
and PHA-E 0.75mg/ml identified proximal tubules (Vector Labora-
tories, Burlingame, CA). Deparaffinized sections were treated with
10 mmol/l citrate buffer, pH 6.0, microwaved, incubated with
primary HGFIN antibody at 4 1C overnight, and detected after
incubation in a dark humid box with Alexa Fluor 594 donkey anti-
goat IgG (Invitrogen, Carlsbad, CA)  30 min at room temperature.
After washing, slides were incubated with either of the fluorescein-
labeled lectins  1 h at room temperature. Sections were rinsed,
mounted with Vectashield (Vector Laboratories) with 4,6-diamidi-
no-2-phenylindole, and visualized under a fluorescence microscope.
Cellular localization. Immortalized MDCT cells (kindly
provided by Dr Peter Friedman) were cultured in 12-well plates
(105 cells/well) and transfected with pEGFP-mHGFIN (kindly
provided by Dr Dietmar Bachner), using FuGENE HD transfection
reagent (Roche, Mannheim, Germany), then fixed with 4%
paraformaldehyde. Transfected MDCT cells were labeled with a1
Na,K-ATPase antibody (1:150; Abcam, Cambridge, MA) overnight
at 4 1C, followed by Alexa Fluor 563 goat anti-mouse secondary
antibody (Invitrogen) for 30 min. Nuclei were labeled with
TO-PRO-3 iodide (1:2500; Invitrogen). Slides were examined using
a confocal laser scanning microscope.
Immunohistochemical colocalization of HGFIN and LC3 II or
phospho-Syk
Serial paraffin-embedded rat C and 5/6Nx sections were depar-
affinized and stained for HGFIN and either LC3 II (1:150 dilution;
Cell Signaling, Danvers, MA) or phosho-Syk (1:100 dilution;
Abcam) at 4 1C overnight. Secondary horseradish peroxidase-conju-
gated goat anti-rabbit IgG (Santa Cruz Biotechnology) was applied
 30 min at room temperature. Immunoreaction was visualized with
diaminobenzidine. Hematoxylin was used as counterstain.
Rat urine HGFIN immunoblotting
Urine was collected overnight on ice with protease inhibitors
(1 mmol/l sodium azide (Sigma, St Louis, MO), phenylmethylsulfo-
nyl fluoride 0.1 mg/ml (Roche, Palo Alto, CA), and leupeptin
0.1 mg/ml (Roche) in 1 M Tris pH 6.8 in a 1:10 ratio of buffer to
urine) before surgery and after 2 days, 2 weeks and 4 weeks, and
then aliquoted and frozen at 80 1C. Before immunoblotting,
thawed samples were centrifuged at 1000 g  5 min and concen-
trated by microcentrifugation.51 Then, 2% of the urine volume was
applied to the Microcon YM-10 centrifugal filter (Millipore,
Billerica, MA) and centrifuged at 14,000 r.p.m.  30 min. Concen-
trated urine was diluted with 30 ml of 10 mmol/l Tris-HCL buffer
(pH 7.4, centrifuged twice, each sample mixed with Laemmli
loading buffer with 75 mg/ml of dithiothreitol, heat inactivated
 5 min, and subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis followed by immunoblotting with anti-HGFIN
antibody 1:1000 (R&D Laboratories). Results were normalized to
urine creatinine concentration.
Human uHGFIN immunoblotting
Spot urines were placed on ice with or without protease inhibitors
(167 ml of 1 M sodium azide, 250ml of 100 mmol/l phenylmethylsul-
fonyl fluoride, 100ml of 10 mmol/l leupeptin per 50 ml urine
volume), aliquoted, and stored at 80 1C. Before immunoblotting,
samples were thawed, centrifuged at 1000 g  5 min, then
centrifuged lightly, (4 1C at 1000 r.p.m.  5 min); medium (30 ml
of urine supernatant was applied to a Microcon YM-10 centrifugal
filter (Millipore) and centrifuged at 14,000 r.p.m.  30 min); or
ultracentrifuged for exosomes as described.52 Aliquots (5 ml) were
diluted (1:5) with 10 mmol/l Tris-HCL buffer pH 7.4. Equal volumes
of 2 Laemmli loading buffer with 74 mg/ml dithiothreitol were
added, heat-inactivated  5 min, and subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis. Anti-HGFIN antibody
1:2000 (R&D Laboratories) was used for immunoblotting. Results
were normalized to urine creatinine concentration.
uHGFIN and uNGAL ELISA
Urine from proteinuric patients with progressive kidney disease
(n¼ 21), PCKD (n¼ 5), healthy controls (n¼ 20), and nonpro-
gressive proteinuric kidney disease (n¼ 2) was aliquotted and stored
at 80 1C until use. uHGFIN was measured using a sandwich ELISA
(Gpnmb Duoset; R&D Systems) as directed. HGFIN absorbance was
measured at 450 nm and corrected for plate artifact at 570 nm.
Concentrations were calculated based on a log-transformed
standard curve. Standards and samples were run in triplicate and
averaged. To show recoverability from urine, ELISA was also
performed on a negative control urine specimen to which HGFIN
standards were added to replicate the standard curve. uNGAL ELISA
measurements were performed using a commercial assay (NGAL
Rapid ELISA Kit 037; Bioporto, Grusbakken, Denmark) as directed
and expressed in ng/mg creatinine.
Statistics
Results are expressed as mean±s.d. The analyses used SPSS for
Windows Ver 5.1 (SPSS, Chicago, IL) and StatMost (Salt Lake City,
UT). For multiple comparisons, analysis of variance was used
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followed by the least significance difference test or the Kolomorov–
Smirnov test. For nonparametric data, the Mann–Whitney
U-test (two tailed) was used. ELISA sensitivity measurements were
calculated as number of true positives/number of true posi-
tivesþ false negatives. Specificity was calculated as number of true
negatives/number of true negativesþ false positives. Significance is
assigned at Po0.05.
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